Moderna (MRNA) Stock Forecast & Predictions for 2024, 2025, 2026–2030 and Beyond

Moderna is an American pharmaceutical company that focuses on developing medicines based on messenger ribonucleic acid (mRNA). It is best known for creating the Moderna COVID-19 vaccine.

MRNA stock price forecasts are based on a thorough analysis of current market trends and the company’s financial performance. A comprehensive assessment provides insight into the future performance of MRNA stock quotes. Currently, analysts predict a decline in the stock price, with estimates varying. 

This article examines expert forecasts of MRNA rates for the years ahead and considers all factors that can influence the asset’s price.

The article covers the following subjects:

Major Takeaways

• The current price of #MRNA is $39.38 as of 21.12.2024.
• The MRNA price reached its all-time high of $484.47 on 2021-08-09. The stock’s all-time low of $12.26 was recorded on 2019-08-05.
• LongForecast expects the Moderna stock to decline in 2025, followed by a correction. The anticipated price range is $17.18 to $38.19. In contrast, WalletInvestor projects that the rate may hit a new all-time low in 2025.
• LongForecast predicts that the MRNA price will continue declining until the end of 2026. GovCapital estimates that the price will fluctuate between $38.62 and $58.59.
• Long-term forecasts for 2027–2030 vary considerably. However, most analysts concur that the asset’s price will likely slide to $11.
• Since the end of the pandemic, the demand for the vaccine has decreased significantly, pushing MRNA’s share price considerably lower.
• Financial reports, the Zacks Rank, and other factors may have a substantial influence on the asset’s price.

MRNA Real-Time Market Status

The #MRNA stock is trading at $39.38 as of 21.12.2024.

It is essential to pay close attention to the following key indicators to gain a clear insight into the current state of the MRNA stock:

• Market capitalization is defined as the total value of a company’s outstanding shares of stock in the market. It provides insight into the company’s significance and the extent of its reliance on other firms within the industry.
• Market sentiment is determined by investors’ mood and perception of a company’s stock. It can be bullish or bearish. This metric is crucial for making informed decisions and predicting future price movements.
• Trading volume is the number of shares bought and sold over a certain period, measuring market participation and conviction. It helps to determine general market sentiment, whether investors understand where the asset’s price is moving, and what trading decisions should be made.
• The price change over the past 12 months shows how a stock’s price has changed during this time, allowing investors to gauge its volatility and underlying trends.

The evaluation of these indicators enables traders and investors to conduct accurate forecasts and make informed trading decisions.

MRNA Stock Price Forecast for 2024–2025 Based on Technical Analysis

It is essential to conduct a technical analysis of the D1 chart to gain insight into the trajectory of the MRNA rate over the next 12 months. To evaluate the current status of the asset and ascertain the prevailing trend, we will use the SMA, EMA, RSI, and MACD indicators.

The chart shows that the trading instrument has been moving within a descending trading channel for an extended period. The asset is currently trading above the EMA and SMA, with the RSI standing at $45.17. These indicators point to an uptrend and a prevailing bullish sentiment. However, the MACD indicator signals a continuation of the downward trend. Therefore, the current growth represents a minor correction before a further decline. 

Let’s plot Bollinger Bands on the chart to gain more precise market insights.

The MRNA price is trading above the middle of the channel, approaching its upper boundary. The standard deviation channel is currently exhibiting significant expansion. In the absence of external factors, it is not clear whether the price will pierce the channel’s boundaries in the near term. This suggests a potential rebound from the upper boundary of the channel at $44.3, followed by a further decline.

The following table provides an overview of projected prices for the next 12 months.

Month	MRNA Shares Projected Values
	Minimum, $	Maximum, $
January	31.42	37.14
February	26.81	31.42
March	22.96	26.81
April	19.86	22.96
May	18.01	19.86
June	16.64	18.01
July	14.17	16.64
August	12.96	14.17
September	13.27	15.58
October	15.58	18.97
November	18.97	23.41
December	23.41	27.81

Long-Term Trading Plan for Moderna Inc. (#MRNA)

With a comprehensive approach, trading MRNA can bring hefty profits, as it is clear what can be expected from the asset in the near term. The current market environment suggests a rebound from the upper boundary of the channel and further price decline. A reversal is possible only under the influence of fundamental factors.

Let’s devise a long-term trading plan for MRNA based on the analysis:

• Consider purchasing the stock in the coming month. However, a rapid bearish reversal is possible.
• The price is projected to reverse to the downside in January 2025. The downtrend may persist until mid-2025, so short positions can be considered.
• If the price reaches $16.17 by the third quarter of 2025, it would be prudent to conduct another technical analysis of the MRNA stock, considering fundamental factors, as another trend reversal is possible.
• Longer-term prospects for two years or more are not precise. It is likely that an external factor, such as the global pandemic, will be required to reverse the current downtrend.

Analysts’ MRNA Shares Price Projections for 2025

In general, the consensus among experts is that the outlook for the instrument is bearish, maintaining its downward trajectory with an anticipated correction by the end of 2025.

LongForecast

Price range in 2025: $17.18–$38.19 (as of 03.12.2024).

According to LongForecast, the MRNA price will continue to decline until mid-2025, followed by a correction in the second half of the year.

Month	Open, $	Min–Max, $	Close, $
January	35.59	27.83–38.19	30.25
February	30.25	23.65–30.25	25.71
March	25.71	20.21–25.71	21.97
April	21.97	17.18–21.97	18.67
May	18.67	17.82–20.92	19.37
June	19.37	18.49–21.71	20.10
July	20.10	20.10–24.97	23.12
August	23.12	22.45–26.35	24.40
September	24.40	24.40–29.28	27.11
October	27.11	25.19–29.57	27.38
November	27.38	25.22–29.60	27.41
December	27.41	27.41–34.04	31.52

WalletInvestor

Price range in 2025: $10.384–$37.262 (as of 03.12.2024).

WalletInvestor experts predict a stable decrease in the asset’s price throughout the year, but the forecast is provided only until September.

Month	Minimum, $	Maximum, $
January	29.948	37.262
February	21.908	29.752
March	20.624	21.824
April	18.994	21.551
May	17.146	18.920
June	13.499	19.190
July	13.440	19.190
August	10.593	19.297
September	10.384	10.806

Analysts forecast a gradual decline in the MRNA share price throughout 2025, making the asset more predictable for investors.

Analysts’ MRNA Shares Price Projections for 2026

Let us examine the analyst forecasts for the MRNA rate in 2026. The majority of experts anticipate a recovery in the trading instrument’s price.

GovCapital

Price range in 2026: $38.62–$58.59 (as of 03.12.2024).

GovCapital offers an optimistic forecast. The asset will close the year near $58.59, reflecting a significant gain compared to the final figure at the end of 2025.

Month	Open, $	Close, $
January	38.62	41.01
February	41.80	41.45
March	40.67	43.69
April	43.69	45.81
May	45.81	45.07
June	46.78	50.57
July	50.57	44.65
August	45.51	44.82
September	44.22	45.90
October	44.08	49.29
November	49.29	50.87
December	50.87	58.59

LongForecast

Price range in 2026: $22.13–$37.77 (as of 03.12.2024).

LongForecast analysts expect a minor correction in the asset’s price followed by a decline.

Month	Open, $	Min–Max, $	Close, $
January	31.52	30.38–35.66	33.02
February	33.02	31.52–37.00	34.26
March	34.26	32.17–37.77	34.97
April	34.97	32.27–37.89	35.08
May	35.08	30.27–35.53	32.90
June	32.90	28.61–33.59	31.10
July	31.10	27.56–32.36	29.96
August	29.96	23.94–29.96	26.02
September	26.02	26.02–31.82	29.46
October	29.46	23.04–29.46	25.04
November	25.04	22.36–26.24	24.30
December	24.30	22.13–25.97	24.05

Analysts’ forecasts for 2026 reveal a divergence of opinion. Those who anticipate a decline in price in 2025 are betting on a reversal to the upside, while those who provide more neutral forecasts for 2025 are more optimistic about the stock’s performance in 2026. Nevertheless, the stock is unlikely to exhibit rapid growth predicted earlier.

Analysts’ MRNA Shares Price Projections for 2027

Expert forecasts for 2027 point to a recovery in the MRNA price.

GovCapital

Price range in 2027: $58.24–$75.68 (as of 03.12.2024).

GovCapital indicates that the asset will continue to grow until the fourth quarter of 2027. After that, the price will likely correct to the levels seen at the beginning of the year.

Month	Open, $	Close, $
January	59.72	60.96
February	60.96	64.30
March	64.30	69.78
April	71.13	66.71
May	67.96	75.68
June	75.68	70.66
July	70.66	71.72
August	70.36	73.87
September	73.87	74.63
October	74.63	67.82
November	69.13	62.99
December	61.80	58.24

LongForecast

Price range in 2027: $13.06–$34.35 (as of 03.12.2024).

LongForecast analysts remain bearish about the asset. The Moderna stock will close near $18.38 in December, losing more than 50% on a yearly basis.

Month	Open, $	Min–Max, $	Close, $
January	24.05	24.05–29.87	27.66
February	27.66	27.66–34.35	31.81
March	31.81	24.88–31.81	27.04
April	27.04	21.26–27.04	23.11
May	23.11	18.07–23.11	19.64
June	19.64	15.36–19.64	16.70
July	16.70	13.06–16.70	14.20
August	14.20	14.20–17.64	16.33
September	16.33	15.86–18.62	17.24
October	17.24	17.24–20.68	19.15
November	19.15	16.91–19.85	18.38
December	18.38	16.84–19.76	18.30

The GovCapital model suggests a gradual increase in the MRNA price, while LongForecast indicates a decline of over 50%. Notably, longer-term forecasts are less reliable, and this discrepancy between the estimates highlights this.

Analysts’ MRNA Shares Price Projections for 2028

Analysts’ forecasts for 2028 also reveal a divergence of opinion. While the prevailing view is that prices will recover, some experts project that Moderna shares will demonstrate flat trading.

GovCapital

Price range in 2028: $50.39–$62.62 (as of 03.12.2024).

GovCapital analysts believe that the asset’s price will trade in a relatively narrow range between $50.39 and $62.62 in 2028, with no sharp fluctuations expected.

Month	Open, $	Close, $
January	58.24	57.41
February	58.52	56.51
March	56.51	53.89
April	52.87	56.16
May	55.10	52.89
June	52.89	58.27
July	58.27	57.35
August	58.46	56.12
September	56.12	54.32
October	54.32	50.39
November	51.36	52.16
December	53.17	62.62

LongForecast

Price range in 2028: $10.82–$23.81 (as of 03.12.2024).

Analysts at LongForecast expect a modest deceleration in the decline of the asset price, although the prevailing downward trajectory is likely to persist. By the end of 2028, the asset is projected to reach $11.76, representing a 75% loss on a yearly basis.

Month	Open, $	Min–Max, $	Close, $
January	18.30	18.30–22.73	21.05
February	21.05	20.29–23.81	22.05
March	22.05	17.24–22.05	18.74
April	18.74	15.82–18.74	17.20
May	17.20	15.63–18.35	16.99
June	16.99	14.66–17.20	15.93
July	15.93	13.86–16.26	15.06
August	15.06	13.35–15.67	14.51
September	14.51	11.59–14.51	12.60
October	12.60	12.60–15.40	14.26
November	14.26	11.15–14.26	12.12
December	12.12	10.82–12.70	11.76

Analytical agencies give forecasts that mirror the rates projected in 2026. Conversely, the GovCapital model suggests a potential for price stagnation rather than continued growth.

Analysts’ MRNA Shares Price Projections for 2029

Forecasts for 2029 are inherently less reliable due to the increased difficulty in making accurate predictions over such an extended period. The forecasts presented in this section serve as a reference only and can be used as a benchmark for setting long-term goals. However, it is essential to regularly review and adjust your trading plan in line with changing market conditions.

GovCapital

Price range in 2029: $46.84–$62.62 (as of 03.12.2024).

GovCapital analysts believe that MRNA shares will demonstrate correction to levels seen in 2025.

Month	Open, $	Close, $
January	53.17	62.62
February	62.62	60.26
March	61.42	61.32
April	60.70	62.52
May	56.80	55.12
June	54.08	54.54
July	54.92	54.40
August	54.40	52.11
September	51.13	51.31
October	51.81	46.84
November	46.84	48.46
December	48.46	n/a

Forecasts for 2029 indicate that the exchange rate will likely correct to 2025 levels. However, the accuracy of such predictions is extremely approximate, as they do not consider the influence of fundamental factors.

Analysts’ MRNA Shares Price Projections for 2030

Analytical forecasts for 2030 also differ. Some project that the MRNA stock will see a steady upward trend, while others expect it to depreciate.

StockScan

Price range in 2030: $197.32–$317.13 (as of 03.12.2024).

StockScan analysts believe that the asset will soar significantly by 2030 and continue to grow further. At the end of the year, it may reach $317.13, up about 600% from 2025.

Month	Minimum, $	Average, $	Maximum, $
January	197.32	199.51	202.65
February	200.53	206.47	207.46
March	208.22	213.18	213.94
April	214.16	224.50	224.54
May	225.27	235.05	235.62
June	235.71	244.51	244.63
July	246.11	258.57	258.64
August	259.80	266.04	266.19
September	267.54	273.86	275.51
October	275.19	283.90	287.63
November	284.88	293.45	305.04
December	297.49	316.30	317.13

CoinCodex

Price range in 2030: $14.17–$27.63 (as of 03.12.2024).

CoinCodex analysts predict the price of MRNA will decline in 2030. The average price will be $24.40 in January, sliding to $22.40 by December. Notably, LongForecast has predicted similar price levels as early as 2029.

Month	Minimum, $	Average, $	Maximum, $
January	17.75	24.40	27.63
February	16.78	18.07	19.76
March	15.50	19.08	21.45
April	16.62	18.25	20.82
May	15.10	16.35	17.65
June	14.28	16.18	17.92
July	18.35	19.64	20.90
August	16.02	18.78	22.59
September	14.17	15.47	16.83
October	14.41	15.74	18.24
November	17.53	20.34	21.94
December	20.55	22.40	24.53

Forecasts for 2030 reflect divergence in outlooks regarding price projections for the Moderna stock. Forecasting price behavior over such an extended period is inherently challenging. As a result, it is not possible to determine which scenario is the most probable.

Analysts’ MRNA Shares Price Projections until 2050

As previously stated, long-term forecasts are not characterized by a high degree of accuracy. As a result, it is exceedingly difficult to find forecasts for 10 years or longer time horizons. When it comes to currencies or commodities, it is possible to make more or less reasonable assumptions of how their price may change over 10 years or more. However, this is not the case with stocks.

It is important to recognize that a number of factors could influence the value of shares by 2050. Many unforeseen fundamental factors could affect the value of shares. In the case of Moderna, new patents and developments could boost the company’s stock. In addition, the company may face financial hurdles that could lead to its bankruptcy and dissolution.

Market Sentiment for Moderna Inc. (#MRNA) on Social Media

In the context of asset analysis, media sentiment measures the emotional tone of posts on social media, news, forums, and other online platforms to gain insight into public opinion about a particular trading instrument or company.

Let’s examine posts on social network X (formerly known as Twitter) which mention MRNA to gain a better understanding of the media sentiment surrounding the company’s stock.

User @J. believes that the company should modify its current policy and focus on acquiring smaller companies, as Moderna’s business model is unsustainable.

The company is frequently cited in a negative context with regard to the Moderna vaccine or the associated production costs, as evidenced by references on the Joe Rogan podcast and in a post by @BernieSanders.

In general, there is a great deal of skepticism surrounding the development and principles of the vaccine for the novel coronavirus, which is exerting significant pressure on the company’s stock.

MRNA Price History

Moderna reached its all-time high of $484.47 on 2021-08-09. The lowest price of MRNA was recorded on 2019-08-05 when the stock declined to $12.26.

Below is a chart showing the performance of #MRNA over the last ten years. In this connection, it is important to evaluate historical data to make predictions as accurate as possible.

Between January 2019 and December 2022, the Moderna stock exhibited high volatility and robust growth, mirroring the dynamic evolution of the biotechnology sector. The stock price began the year at $16.60 and saw a steady increase, reaching $20.35 by March 2019.

The pivotal moment occurred in 2020 amidst a global health crisis. Moderna’s contributions to the development of a coronavirus vaccine drove the stock price from $25.93 in February 2020 to a high of $173.16 in January 2021, showcasing an unparalleled surge. However, the peak was followed by fluctuations, with the stock price reaching a high of $497.49 in July 2021. After that, the stock began to slide, reaching a low of $179.62 in December 2022.

In 2023, MRNA’s stock price experienced a significant decline from $204.1 in January to a low of $65.27 in November. Nevertheless, the price has been on a gradual upward trajectory, reflecting a sustainable bullish trend.

However, this upward movement proved to be short-lived. The period following the conclusion of the pandemic impacted all pharmaceutical companies. At present, the company’s shares are experiencing a downtrend, and it is unlikely that there will be any significant shifts in the near future.

MRNA Shares Fundamental Analysis

Fundamental analysis involves evaluating a company’s performance based on its financial and operational metrics. In this section, we examine the key factors influencing Moderna’s share price, including economic conditions, technological innovation, and regulatory risks.

What Factors Affect the #MRNA Stock?

The MRNA share price movement depends on a variety of fundamental factors:

• Patents relating to mRNA technology. The COVID-19 pandemic challenged pharmaceutical companies, pushing their stocks higher with the development of coronavirus vaccines, but now the price is slowly declining.
• Regulatory changes. The regulatory landscape for healthcare companies can both increase and decrease research and manufacturing costs.
• Macroeconomic conditions. Inflation, interest rates, and geopolitical events affect MRNA stocks. During periods of economic uncertainty, investors often shift their priorities and turn to safe-haven assets to preserve their capital. Against this backdrop, stocks may see wide fluctuations.
• Consumer spending. In the absence of global risks of emerging infectious diseases, the development of new vaccines is greatly diminished. As a result, investors are reluctant to invest in expensive research.

More Facts About Moderna Inc. (#MRNA)

Moderna, Inc. is one of the largest biotechnology companies in the United States, specializing in the development of messenger RNA-based drugs. The company was founded in 2010.

During the COVID-19 pandemic, Moderna, Inc. was developing a coronavirus vaccine, which caused its stock price to rise significantly. In addition, MRNA was included in the S&P 500 Index on July 21, 2021, replacing the pharmaceutical company Alexion Pharmaceuticals. These two factors attracted investors to Moderna, Inc., but it was a short-lived interest.

Advantages and Disadvantages of Investing in #MRNA

Investing in MRNA shares has its advantages and disadvantages, which are important to consider when making decisions. Below are the main pros and cons of investing in this asset.

Advantages

• Research in the field of messenger RNA (mRNA) therapeutics will continue over the foreseeable future, as this technology can solve many scientific and medical problems.
• MRNA is included in the S&P 500 index, which indicates its significant market presence. This factor provides a high degree of confidence that the company is trusted by investors and consumers.
• The company has multiple active contracts for vaccine development, including those from the Biomedical Advanced Research and Development Authority (BARDA) within the US Department of Health and Human Services (HHS).

Disadvantages

• As a rule, the stock performance of pharmaceutical companies tends to be relatively stable, with significant shifts only occurring in response to global events, such as the recent pandemic.
• Moderna, Inc. could potentially be acquired by a larger and more successful pharmaceutical company.
• Significant research advancements by competitors could potentially erode the company’s position in the sector, and such scenarios are challenging to predict.

Remember that financial markets can be highly unpredictable. Although MRNA can be considered a stable asset, the risks of loss cannot be completely eliminated.

How We Make Forecasts

We employ a comprehensive methodology to build forecasts:

• Short-term forecasts are based on current market data, including analysis of technical indicators to identify the current trend on lower time frames.
• Medium-term forecasts include assessing key fundamental factors such as quarterly reports, earnings, the debt-to-equity ratio, dividends, company reputation, technologies it uses, etc.
• Long-term forecasts rely on long-term trends and patterns specific to the industry, including the company’s position in its sector and forecasts by independent analysts.

In order to make an accurate and comprehensive forecast, we consider both internal factors affecting the price of an asset and external factors.

Conclusion: Is MRNA a Good Investment?

The Moderna (MRNA) stock continues to attract both traders and investors. LongForecast projections indicate a downward trajectory, a view that is shared by several analytical agencies. This indicates that short-term short positions can be opened.

The Moderna stock is a promising asset, as it is expected to showcase a predictable price trajectory in the next few years. The company’s stable position in the sector emphasizes its potential, which makes it possible to consider long positions in the long term. However, it is advisable to adjust your trading plan regularly to avoid financial losses.

Price chart of MRNA in real time mode

Feed from Litefinance.com

MoneyMaker FX EA Trading Robot